Petoukhova Anna, Snijder Roland, Vissers Thomas, Ceha Heleen, Struikmans Henk
Haaglanden Medical Centre , Department of Medical Physics, Leidschendam, The Netherlands.
Haaglanden Medical Centre , Medical Library, Leidschendam, The Netherlands.
Phys Med Biol. 2023 Sep 8;68(18). doi: 10.1088/1361-6560/acf2e4.
dosimetry (IVD) is an important tool in external beam radiotherapy (EBRT) to detect major errors by assessing differences between expected and delivered dose and to record the received dose by individual patients. Also, in intraoperative radiation therapy (IORT), IVD is highly relevant to register the delivered dose. This is especially relevant in low-risk breast cancer patients since a high dose of IORT is delivered in a single fraction. In contrast to EBRT, online treatment planning based on intraoperative imaging is only under development for IORT. Up to date, two commercial treatment planning systems proposed intraoperative ultrasound or in-room cone-beam CT for real-time IORT planning. This makes IVD even more important because of the possibility for real-time treatment adaptation. Here, we summarize recent developments and applications of IVD methods for IORT in clinical practice, highlighting important contributions and identifying specific challenges such as a treatment planning system for IORT. HDR brachytherapy as a delivery technique was not considered. We add IVD for ultrahigh dose rate (FLASH) radiotherapy that promises to improve the treatment efficacy, when compared to conventional radiotherapy by limiting the rate of toxicity while maintaining similar tumour control probabilities. To date, FLASH IORT is not yet in clinical use.
剂量测定(IVD)是外照射放疗(EBRT)中的一项重要工具,可通过评估预期剂量与实际给予剂量之间的差异来检测重大误差,并记录个体患者所接受的剂量。此外,在术中放疗(IORT)中,IVD对于记录给予的剂量也高度相关。这在低风险乳腺癌患者中尤为重要,因为IORT的高剂量是单次给予的。与EBRT不同,基于术中成像的在线治疗计划仅在IORT中处于开发阶段。到目前为止,有两种商业治疗计划系统提出了术中超声或室内锥形束CT用于实时IORT计划。由于实时治疗调整的可能性,这使得IVD变得更加重要。在此,我们总结了IVD方法在IORT临床实践中的最新进展和应用,强调了重要贡献并识别了特定挑战,如IORT的治疗计划系统。未考虑将高剂量率近距离放疗作为一种给予技术。我们还增加了用于超高剂量率(FLASH)放疗的IVD,与传统放疗相比,FLASH放疗有望通过限制毒性发生率同时保持相似的肿瘤控制概率来提高治疗效果。迄今为止,FLASH IORT尚未应用于临床。